ACCESS Newswire

Trilogy International Partners Inc.

Share
Trilogy International Partners Inc. Announces Future Board Chair for New Zealand Subsidiary

BELLEVUE, WA / ACCESSWIRE / July 28, 2021 / Trilogy International Partners Inc. (TSX:TRL), an international wireless and fixed broadband telecommunications operator, today announced that Mark Cairns will be chair of the board of its New Zealand subsidiary, 2degrees, subsequent to a successful IPO.

Mr. Cairns is a widely respected Chief Executive and Company Director with significant public company leadership expertise across New Zealand.

In the first half of 2021, 2degrees announced that it was preparing for a partial public listing on the New Zealand Stock Exchange and the Australian Securities Exchange by the end of this year. The completion of the listing remains subject to market conditions. However, it is customary in New Zealand that the chair of a publicly listed company be an independent director, who is identified in advance of the public listing.

About Trilogy International Partners Inc.

Trilogy International Partners Inc. is the parent company of Trilogy International Partners LLC ("Trilogy LLC"), a wireless and fixed broadband telecommunications operator formed by wireless industry veterans John Stanton, Theresa Gillespie and Brad Horwitz. Trilogy LLC's founders have an exceptional track record of successfully buying, building, launching and operating communications businesses in 15 international markets and the United States.

Trilogy LLC currently provides wireless communications services through its operating subsidiaries in New Zealand and Bolivia. Its head office is located at 155 108th Avenue NE, Suite 400, Bellevue, Washington, 98004.

For more information, visit www.trilogy-international.com.

Cautionary Statements Regarding Forward Looking Information

Certain information contained in this news release may be "forward-looking information" within the meaning of applicable securities laws in Canada and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 of the United States of America. Forward-looking information and forward-looking statements are often, but not always identified by the use of words such as "expect", "anticipate", "believe", "foresee", "could", "estimate", "goal", "intend", "plan", "seek", "will", "may" and "should" and similar expressions or words suggesting future outcomes. This news release includes forward-looking information and statements pertaining to, among other things, the expected appointment of a new board chair in the 2degrees business. Numerous risks and uncertainties could cause the actual events and results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.

Please see "Risks Factors" in our Annual report available under the Company's profile at www.sedar.com, which is also included with the Company's Annual Report on Form 20-F under the Company's profile at www.sec.gov, for information on the risks and uncertainties associated with our business. Readers should not place undue reliance on forward-looking information and statements, which speak only as of the date made. The forward-looking information and statements contained in this release represent our expectations as of the date of this release. We disclaim any intention or obligation or undertaking to update or revise any forward-looking information or statements whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

Media Contact:

Ann Saxton
425-458-5900
Ann.Saxton@trilogy-international.com
Vice President, Investor Relations & Corporate Development

SOURCE: Trilogy International Partners Inc.



View source version on accesswire.com:
https://www.accesswire.com/657434/Trilogy-International-Partners-Inc-Announces-Future-Board-Chair-for-New-Zealand-Subsidiary

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 13:00:00 CET | Press release

Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome

Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud28.10.2025 13:00:00 CET | Press release

ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace. SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows. Bringing the Florence Trial Operations Platform Benefits to AWS As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years. The platform enables: Faster Startup: Up to 70% faster study activation timelines through automa

GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 10:00:00 CET | Press release

Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa

Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release

With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi

Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India27.10.2025 13:45:00 CET | Press release

Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad's Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continui

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye